Reishi Mushroom for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Reishi Mushroom for Health & Longevity

Created on 08/15/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Dried fungus taken as powder, capsule or tea. The most consistent human finding is a shift in the mix of circulating immune cells, seen when added to cancer treatment. Weaker signals for urinary symptoms in men, tiredness, blood fats and insulin. Low-cost, narrow upside, one rare but serious danger: unpredictable liver injury. Label accuracy is poor. (Full Review)

Protocol

Conventional supplement protocol
1.5–5.2 g daily
Basic dried extract, most commonly 5.2 g split as three 1,800 mg doses
Traditional decoction approach
6–12 g daily
Dried sliced fruiting body simmered 1 to 2 hours and drunk as tea
Concentrated triterpenoid extract
6 mg daily
Ethanol extract, the regimen used for urinary symptoms
Time to effect
Immune markers
8 weeks
Nothing measurable should be expected before two months
Urinary symptoms and fatigue
8–12 weeks
Symptom scores only; objective urinary measures did not change
Blood lipids
12 weeks
If the marker that motivated use has not moved by 12 weeks, continuing is unsupported

Benefits

Contraindications
  • Active or chronic liver disease, or baseline ALT or AST above 1.2 times the upper limit of normal
  • Bleeding disorder, platelet count below 100,000/mm³, or clotting time above 1.5 times the upper limit of normal
  • Within 14 days of planned surgery or an invasive procedure
  • Solid organ transplant recipients and others on deliberate immunosuppression
  • Known mushroom or fungal allergy
  • Pregnancy and breastfeeding (absence of safety data)
    •
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)
  • Glucose-lowering medication (metformin, gliclazide, insulin, empagliflozin)
  • Antihypertensives (lisinopril, amlodipine)
  • Drugs cleared by CYP3A4 and CYP2D6 (simvastatin, ciclosporin, tamoxifen, paroxetine)
  • Checkpoint inhibitors (pembrolizumab, nivolumab)
  • Over-the-counter agents (aspirin, ibuprofen and other NSAIDs, paracetamol)
  • Supplements with additive bleeding effect (fish oil, high-dose vitamin E, ginkgo, garlic extract, nattokinase)
  • Supplements with additive glucose-lowering effect (berberine, chromium, alpha-lipoic acid, cinnamon extract)
  • Other immune-active mushrooms (turkey tail, maitake, chaga, AHCC)
    •

Risk & Side Effects

  • High: Mild gastrointestinal and mucosal dryness symptoms
    •
  • Medium: Idiosyncratic liver injury
    •
  • Low: Bleeding risk with antiplatelet or anticoagulant therapy; additive blood-glucose lowering
    •
  • Speculative: Eosinophilic reaction with liver nodule formation; direct toxicity to immune cells at high concentrations; flare of immune-mediated muscle injury; false-positive fungal infection blood test
    •

Monitoring

Marker Target Why
ALT 10–26 U/L (men), 8–22 U/L (women) Primary early signal of drug-induced liver injury
AST 10–26 U/L Confirms hepatic origin alongside ALT
GGT <20 U/L (men), <15 U/L (women) Most sensitive marker of hepatic and biliary stress and of alcohol load
Total bilirubin 0.3–1.0 mg/dL Distinguishes a benign enzyme rise from genuine liver dysfunction
Platelet count 200,000–350,000/mm³ Baseline safety gate for the theoretical antiplatelet effect
PT/INR 0.9–1.1 Detects any real change in clotting, which trials did not find
Fasting insulin 2–5 µIU/mL The metabolic marker that moved in the positive trial
HbA1c 4.8–5.4% Confirms whether any insulin change reaches longer-term glucose control
Triglycerides <80 mg/dL The lipid fraction that responded to spore oil
hs-CRP <0.5 mg/L Tracks the anti-inflammatory shift claimed for the immune effect
Lymphocyte subsets (CD3, CD4, CD8) No established target; track change from the individual's own baseline The outcome with the strongest trial evidence behind it
IPSS <8 points (mild) The endpoint for the male urinary indication

Cadence: Baseline, then liver panel and full blood count at 8 to 12 weeks and every 6 months while use continues; metabolic and inflammatory markers rechecked at 12 weeks; immediately if fatigue, nausea, dark urine or yellowing of the skin appears.

Qualitative Assessment

  • Sleep quality and time to fall asleep, given evening dosing and the mixed insomnia signal
  • Daytime energy and perceived fatigue, the outcome with the largest reported subjective effect
  • Sense of well-being and stress tolerance
  • Digestive comfort, dry mouth and dry throat, the earliest and most common adverse events
  • Frequency and duration of respiratory infections across a full season
  • Unexplained tiredness, appetite loss, dark urine or itching, any of which warrants stopping and testing immediately
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.